Search research articles
Contact Us
Filters
Showing results (91-100 of 104) with videos related to
Page
of 11
Sort By:
Lancet (London, England)
|
September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Frontiers in Immunology
|
November 10, 2025
Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults
Kwadwo Ansah Koram, Kathleen A Walker, Bonaventure Orizu, et al.
Vaccine
|
July 13, 2021
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
Karen E Gooch, Trevor R F Smith, Francisco J Salguero, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 30, 2013
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge
Vainav Patel, Rashmi Jalah, Viraj Kulkarni, et al.
Cell Reports
|
November 15, 2018
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model
Ami Patel, Daniel H Park, Carl W Davis, et al.
Cell Reports
|
January 29, 2022
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
Kylie M Konrath, Kevin Liaw, Yuanhan Wu, et al.
The Journal of Infectious Diseases
|
October 11, 2018
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
Ami Patel, Emma L Reuschel, Kimberly A Kraynyak, et al.
NPJ Vaccines
|
December 22, 2017
<i>In vivo</i> protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
Karuppiah Muthumani, Bryan D Griffin, Sangya Agarwal, et al.
Journal of Virology
|
May 26, 2018
Control of Heterologous Simian Immunodeficiency Virus SIV<sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques
Shakti Singh, Eric G Ramírez-Salazar, Rami Doueiri, et al.
Nature Communications
|
October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2
Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 104) with videos related to
Sort By:
Page
of 11
Lancet (London, England)
|
September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Frontiers in Immunology
|
November 10, 2025
Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults
Kwadwo Ansah Koram, Kathleen A Walker, Bonaventure Orizu, et al.
Vaccine
|
July 13, 2021
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
Karen E Gooch, Trevor R F Smith, Francisco J Salguero, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 30, 2013
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge
Vainav Patel, Rashmi Jalah, Viraj Kulkarni, et al.
Cell Reports
|
November 15, 2018
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model
Ami Patel, Daniel H Park, Carl W Davis, et al.
Cell Reports
|
January 29, 2022
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
Kylie M Konrath, Kevin Liaw, Yuanhan Wu, et al.
The Journal of Infectious Diseases
|
October 11, 2018
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
Ami Patel, Emma L Reuschel, Kimberly A Kraynyak, et al.
NPJ Vaccines
|
December 22, 2017
<i>In vivo</i> protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
Karuppiah Muthumani, Bryan D Griffin, Sangya Agarwal, et al.
Journal of Virology
|
May 26, 2018
Control of Heterologous Simian Immunodeficiency Virus SIV<sub>smE660</sub> Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques
Shakti Singh, Eric G Ramírez-Salazar, Rami Doueiri, et al.
Nature Communications
|
October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2
Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
Page
of 11